Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
Posted on: Wednesday, 13 May 2009, 12:42 CDT
Monteris Medical Earns 510(k) Clearance for AutoLITT(TM)
The AutoLITT System uses an MRI-guided laser probe, passed through a small bur hole in the skull, to deliver laser interstitial thermal therapy ("LITT") to heat and coagulate the tumor from the inside. High-intensity laser energy is applied directly to the tumor, rather than passing through normal tissue, while the MRI measures the temperature inside the brain, showing thermal damage as it happens and facilitating precise control of the treatment. Once coagulated, the treated tumor mass is dead.
"The AutoLITT procedure delivers new-found hope for patients who have previously been given limited options in the treatment of their tumors," explains
About Monteris Medical
Monteris Medical(TM) Inc. is a medical device company dedicated to developing new cancer treatment technologies that improve clinical outcomes, quality of life, and the cost and complexity of care. The company's U.S. corporate headquarters are in
SOURCE Monteris Medical Inc.
Source: PR Newswire
Related Articles
- Local Neurosurgeon Co-Authors National Treatment Guidelines for Brain Tumor Patients
- Cutting Edge Laser Vein Treatments Available in Los Angeles Area Clinic (laserandveinclinic.com)
- Greenway Medical Technologies' PrimePatient Solution Transforms Physician/Patient Relationship Through Enhanced Communication Channels and Improved Workflows
- Laser light used to make brain gamma waves
- Modifying Treatment For Elderly Brain Cancer Patients
- RTOG Study Likely Treatment Option for Brain Tumor Patients Like Sen. Kennedy
- Patients of Brain Malaria Found in Southern Nepal
- Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients With Brain Metastases Originating From Breast Cancer
- Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating From Breast Cancer
- Updated Results of Allos' Phase 3 Reach Study Confirm Survival Benefit in Patients With Brain Metastases From Breast Cancer
User Comments (0)

RSS Feeds